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Osteoarthritis and Cartilage 22 (2014) 1347e1348EditorialA special Osteoarthritis and Cartilage issue on imaging in osteoarthritisOsteoarthritis is a highly prevalent and disabling disease that
consequently has a formidable individual and societal impact. At
present there are no therapies that have been approved by regula-
tory authorities to modify the course of the disease. Indeed, the
recent failure of a number of phase II and III clinical trials for oste-
oarthritis structure-modifying drugs has resulted in a considerable
decline in the number and size of pharmaceutical company
research programs in this area1. The reasons for the translational
failure of anti-osteoarthritis drugs are likely multifold, but include
the poor relationship in individual patients between joint struc-
tural pathology (especially joint space narrowing on radiographs)
and symptomatic disease, and limited responsiveness of existing
approved biomarkers2. Instead, we are faced with the current clin-
ical circumstance of “watchful waiting” or steady decline to end-
stage joint disease and attendant disablement and loss of quality
of life3. Further the available symptom-modifying (analgesic) treat-
ments have only moderate long-term effect sizes with the majority
of patients dissatisﬁed with their efﬁcacy1,4.
This special issue of Osteoarthritis and Cartilage focuses on imag-
ing in osteoarthritis. It is entitled “Imaging in Osteoarthritis: The
breakthrough decade?” We have been saying this for years, but
are we any closer to the pivotal breakthrough? There have been
major research advances that have signiﬁcantly increased our un-
derstanding of the molecular pathophysiology of joint destruction
and pain in osteoarthritis. Preclinical studies with varying levels
of efﬁcacy suggest that a wide array of agents including glucos-
amine sulfate, chondroitin sulfate, sodium hyaluronan, doxycycline,
MMP inhibitors, bisphosphonates, calcitonin, diacerein and
avocado-soybean unsaponiﬁables can modify disease progression1.
Recent disease modiﬁcation trials5,6 highlight the fact that we can
potentially modify the structural course of OA measured using so-
phisticated imaging techniques and suggest we are truly on the
verge of being able to modify this disease. How has this come
about?
A critical ﬁrst step in modifying disease is the ability to objec-
tively measure response to treatment and natural disease progres-
sion. The plethora of imaging research in osteoarthritis over the last
20 years has led to a situation where we can now measure struc-
tural change reliably and with greater responsiveness. Time will
tell whether regulatory approval follows.
The predominant symptom in most patients presenting with
osteoarthritis is pain. Over recent years a number of imaging based
studies have narrowed the discord between structural ﬁndings on
imaging and symptoms7. A thoughtful review by Wenham and
co-authors examines the role of the commonly used imaginghttp://dx.doi.org/10.1016/j.joca.2014.06.009
1063-4584/© 2014 Osteoarthritis Research Society International. Published by Elsevier Lmodalities in clinical practice; both in osteoarthritis management
and differential diagnosis.
ACL injury is a strong risk factor for premature joint deterioration
with osteoarthritic changes being present in 50e70% of the patients
at 10e15 years following the injury8. Estimates suggest that joint
injury accounts for up to 15% of all incident knee OA cases and
that this is also eminently preventable. Unfortunately much of
what we have learned from preclinical research, especially animal
models, has not been immediately translated into improved under-
standing of the human disease. Kijowski and colleagues review this
important area andhighlight the importance of imaging in the acute
setting but also for the long-term prediction of joint health.
Femoroacetabular impingement, estimated to affect 10e25% of
the general population9,10, is a clinical condition that is commonly
associated with anatomical structural changes that may lead to me-
chanical impingement and hip pain in young active adults.
Although untested, the repetitive mechanical impingement in
movement and locomotion is believed to lead to labral and chon-
dral stresses that cause irreversible structural pathology. It is also
believed that this process may be responsible for the development
of a large majority of the cases of hip osteoarthritis11. Given the po-
tential role femoroacetabular impingement plays in predisposing to
osteoarthritis, the role of imaging in this young active population is
crucial to better understand and prevent the later burden of hip
osteoarthritis. This is thoughtfully reviewed by Siebelt and
colleagues.
There is potentially tremendous value to public health in accel-
erating the discovery and development processes for OA therapeu-
tics through shorter studies, using validated responsive endpoints.
The use, in part, of clinical trial evidence based on biomarker and
surrogate endpoint effects (in lieu of morbidity endpoints such as
joint replacement or virtual joint replacement12) has the potential
to revolutionize the osteoarthritis drug development process and
to thereby enhance the armamentarium of safe and effective ther-
apeutics. Imaging is a crucial component in clinical trial develop-
ment and phenotypic characterization of the disease though
imaging will likely help in optimizing trial strategies. This is an
area of great promise but also pitfalls and is critically reviewed by
Eckstein and colleagues.
There are a number of non-osteochondral tissues that can be
affected in osteoarthritis including the synovium, menisci in the
knee, labrum in the hip, ligaments and muscles. These structures
play an important role in maintaining the normal integrity of the
joint and pathologic changes can lead to functional limitations
and pain.td. All rights reserved.
Editorial / Osteoarthritis and Cartilage 22 (2014) 1347e13481348Hayashi and colleagues highlight studies that have established a
relationship between imaging biomarkers and clinical outcomes.
They also provide an excellent overview and recommendations
for imaging protocols for assessment of synovium, meniscus in
the knee, labrum in the hip, and ligaments, and highlight potential
pitfalls in their usage.
There is growing recognition that local perturbation in tissue
biomechanics leads to progressive tissue damage and osteoar-
thritis. The review by Neu discusses emerging functional MRI tech-
niques that complement current MRI methods that provide
structural and compositional information. The ability to non-
invasively measure tissue strain in the intact joint has potential to
address an important knowledge gap between joint kinematics
and cellular mechanotransduction which in the future may
improve our understanding of mechanical drivers of osteoarthritis.
Improved knowledge of the pathogenesis of osteoarthritis and
of its molecular and anatomic pathology and thewealth of informa-
tion relating biomarkers of disease with clinical outcomes will
permit a better means for the assessment of the effects of new ther-
apeutic interventions in OA. Will this decade lead to regulatory
approval of disease modifying drugs and widespread clinical use?
It is difﬁcult to accurately forecast, but we would be greatly sur-
prised if this did not occur. Given the ubiquity of osteoarthritis
and its global burden, ultimately, we will all be the major beneﬁ-
ciaries from the new insights provided into disease risk, character-
ization and treatment. Assuming we maintain a meaningful
motivation with the patient at the forefront of our mind we have
an opportunity to make a difference in millions of people's lives.
Readers of this special issue should know that all reviews and
original research in this issue were subject to full and impartial
peer review, following all procedures that each independently sub-
mitted manuscript undergoes. Wewould like to extend our humble
appreciation to the researchers who submitted articles for this
issue and to our editorial board and all the reviewers that helped
in processing all submitted manuscripts in a limited time frame.
We were impressed with the enthusiastic response from the
research community by its submission of numerous articles for po-
tential inclusion; theywere a pleasure toworkwith andwe are sure
you will see from the contents that it reﬂects wonderful insight and
appraisal of a complex and developing ﬁeld.We hope that this issue
will enlighten readers about the current status of imaging research
and its application in osteoarthritis.
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